BioPharmSignal logoBioPharmSignal

Biotech News

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Abeona Therapeutics (ABEO)Abeona TherapeuticsFDA / regulatory

ABEO (ABEO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is abeo.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

VYGRVoyager Therapeutics2026-06-01 12:00 EST

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

RAREUltragenyx Pharmaceutical2026-08-19 21:21 EST

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

BIIBBiogen2026-06-04 11:30 EST

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

BIIBBiogen2026-07-13 21:38 EST

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

AGIOAgios Pharmaceuticals, Inc.2026-07-07 11:00 EST

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

SRPTSarepta Therapeutics2026-06-30 12:30 EST

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

ABEOAbeona Therapeutics2026-08-13 11:30 EST

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

View all latest news

Abeona Therapeutics

Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases. ZEVASKYN ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform. ABO-701 ABO-701 is an...

Recent company news

ABEOAbeona Therapeutics2026-08-13 11:30 EST

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ABEOAbeona Therapeutics2026-08-04 11:30 EST

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Stock data

Close
6.09 USD
Market cap
324.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States